SCHEDULE: Morgan Stanley Cuts Integra LifeSciences Stake to 4.3%
Beneficial Ownership Disclosure
Morgan Stanley has reduced its beneficial ownership in Integra LifeSciences Holdings Corp. to 4.3%, falling below the 5% threshold.
Summary
- Morgan Stanley filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Integra LifeSciences Holdings Corp.
- As of June 30, 2025, Morgan Stanley ceased to be the beneficial owner of more than five percent of Integra LifeSciences' common stock.
- Morgan Stanley's aggregate beneficial ownership is now 3,379,401 shares, representing 4.3% of the class.
- The firm holds shared voting power over 3,286,867 shares and shared dispositive power over 3,372,686 shares.
- Morgan Stanley holds no sole voting or sole dispositive power over the shares.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as a major institutional investor has reduced its stake below a significant reporting threshold, which can be interpreted as a decrease in conviction or a reallocation of capital.
Negatives
- Morgan Stanley has reduced its beneficial ownership in Integra LifeSciences Holdings Corp. to below the 5% threshold, indicating a decrease in its stake.
Future Outlook
This filing is a disclosure of an institutional investor's ownership change and does not contain forward-looking statements or guidance from Integra LifeSciences Holdings Corp.
Industry Context
Integra LifeSciences Holdings Corp. operates within the healthcare and medical device industry. This filing reflects a change in a major institutional investor's stake, which can be a signal of investor sentiment within the broader market for healthcare companies.
Stakeholder Impact
- Shareholders may interpret the reduction in Morgan Stanley's stake as a potential signal of reduced institutional confidence in Integra LifeSciences, which could influence their investment decisions.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement (Morgan Stanley ceased to be a beneficial owner of more than five percent). |
| 08/05/2025 | Date the Schedule 13G Amendment No. 3 was signed by Morgan Stanley. |
Keywords
Integra LifeSciences, Morgan Stanley, Beneficial Ownership, Schedule 13G, Common Stock, Healthcare, Medical Devices, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.